Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of Two Concentrations of SBI-100 Ophthalmic Emulsion in Patients With Elevated Intraocular Pressure

NCT06144918 is registered in ClinicalTrials.gov with Skye Bioscience, Inc. as lead sponsor.

NCT NCT06144918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06144918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of Two Concentrations of SBI-100 Ophthalmic Emulsion in Patients With Elevated Intraocular Pressure
Lead sponsor
Skye Bioscience, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2023
Completion date
February 22, 2024
Enrollment
56 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open angle glaucoma